Publication | Closed Access

A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes

Hematological MalignancyBone Marrow FailureMedicineMalignant Blood DisorderHematologyPathologyPhase Ii StudyPharmacotherapyPharmacologyOral InhibitorMyelodysplastic SyndromesMyeloid Neoplasia